Antidiabetic and hypolipidemic activity of Helicteres isora in animal models

被引:46
作者
Chakrabarti, R
Vikramadithyan, RK
Mullangi, R
Sharma, VM
Jagadheshan, H
Rao, YN
Sairam, P
Rajagopalan, R
机构
[1] Dr Reddys Res Fdn, Discovery Biol, Hyderabad 500050, Andhra Pradesh, India
[2] Dr Reddys Res Fdn, Discovery Chem, Hyderabad 500050, Andhra Pradesh, India
关键词
Helicteres isora; antidiabetic; lipid; insulin; plasma glucose; peroxisome proliferator activated receptor (PPAR);
D O I
10.1016/S0378-8741(02)00120-4
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
Helicteres isora (Sterculiaceae) root juice has been used in the treatment of diabetes by several ethnic groups in different parts of India. A program was initiated to elucidate the scientific basis for the antidiabetic activity of H. isora. Ethanolic extract of H. isora root caused significant reduction in plasma glucose, triglyceride and insulin levels at 300 mg/kg dose after 9 days of administration to insulin resistant and diabetic C57BL/KsJdb/db mice. In normoglycemic and mildly hypertriglyceridemic Swiss albino mice, the extract also showed significant reduction in plasma triglyceride and insulin levels, without affecting plasma glucose level. An ethanolic extract showed activity distinctly different from glybenclamide and acarbose but similar to troglitazone in these models. In high fat fed hamster model, the extract showed significant reduction in plasma lipid levels. In order to identify the active pharmacophore, the ethanolic extract was further subjected to sequential partitioning with low, medium and high polarity solvents, which yielded a semipurified fraction having both euglycemic and lipid-lowering activity. Our study suggests that the extract of H. isora has insulin-sensitizing and hypolipidemic activity and has the potential for use in the treatment of type-2 diabetes. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:343 / 349
页数:7
相关论文
共 22 条
[1]  
[Anonymous], 1989, DIABETES CARE, V12, P573
[2]   Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: Binding and activation correlate with antidiabetic actions in db/db mice [J].
Berger, J ;
Bailey, P ;
Biswas, C ;
Cullinan, CA ;
Doebber, TW ;
Hayes, NS ;
Saperstein, R ;
Smith, RG ;
Leibowitz, MD .
ENDOCRINOLOGY, 1996, 137 (10) :4189-4195
[3]   NEW PHARMACOLOGICAL APPROACHES TO THERAPY OF NIDDM [J].
BRESSLER, R ;
JOHNSON, D .
DIABETES CARE, 1992, 15 (06) :792-805
[4]  
CAMPBELL IW, 1990, NEW ANTIDIABETIC DRU, P19
[5]  
COWIE CC, 1966, DIABETES VITAL STAT
[6]   PATHOGENESIS OF NIDDM - A BALANCED OVERVIEW [J].
DEFRONZO, RA ;
BONADONNA, RC ;
FERRANNINI, E .
DIABETES CARE, 1992, 15 (03) :318-368
[7]   INSULIN RESISTANCE IN ESSENTIAL-HYPERTENSION [J].
FERRANNINI, E ;
BUZZIGOLI, G ;
BONADONNA, R ;
GIORICO, MA ;
OLEGGINI, M ;
GRAZIADEI, L ;
PEDRINELLI, R ;
BRANDI, L ;
BEVILACQUA, S .
NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (06) :350-357
[8]   15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2) IS A LIGAND FOR THE ADIPOCYTE DETERMINATION FACTOR PPAR-GAMMA [J].
FORMAN, BM ;
TONTONOZ, P ;
CHEN, J ;
BRUN, RP ;
SPIEGELMAN, BM ;
EVANS, RM .
CELL, 1995, 83 (05) :803-812
[9]   CHARACTERIZATION OF CS-045, A NEW ORAL ANTIDIABETIC AGENT .2. EFFECTS ON GLYCEMIC CONTROL AND PANCREATIC-ISLET STRUCTURE AT A LATE STAGE OF THE DIABETIC SYNDROME IN C57BL/KSJ-DB/DB MICE [J].
FUJIWARA, T ;
WADA, M ;
FUKUDA, K ;
FUKAMI, M ;
YOSHIOKA, S ;
YOSHIOKA, T ;
HORIKOSHI, H .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1991, 40 (11) :1213-1218
[10]  
ISHII S, 1996, DIABETES S2, V45, pA141